Eagle Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eagle Pharmaceuticals, Inc.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
The Israeli firm announced a US-wide settlement for opioid crisis litigation that has been hanging over it for years, as forex took its toll on its second-quarter revenues.
Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.
Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Generic Drugs
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Arsia Therapeutics
- Eagle Biologics